f Post-Approval Studies (PAS) Database
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...



Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Study Pending
Application Number /
Requirement Number
P180051 S001/ PAS001
Date Original Protocol Accepted 04/27/2022
Date Current Protocol Accepted  
Study Name OCS-HEART-03-PAS
Device Name OCS Heart System
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population Transit. Adolescent A (distinctively) : 18-21 yrs, Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Objectives Continued follow-up of all living subjects enrolled under IDE G180272, including the Continued Access Protocol subjects. The objective of this study is to characterize the clinical outcomes of these subjects annually through 5 years post-transplant.
Study Population All living subjects enrolled under IDE G180272, including the Continued Access Protocol subjects.
Sample Size All living subjects
Key Study Endpoints patient survival, cardiac-related patient survival, and heart graft survival through 5 years post-transplan.
Follow-up Visits and Length of Follow-up 5 years

OCS-HEART-03-PAS Reporting Schedule

Reporting Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
1 year report 05/03/2023    
2 year report 05/03/2024    
3 year report 05/03/2025    
4 year report 05/03/2026    
final report 09/03/2026    

Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources